Multivariable analysis for PFS
| Risk factor . | Group . | N . | D . | HR (95% CI) . | P . |
|---|---|---|---|---|---|
| Pretreatment × IPSS-R score change | |||||
| Chemotherapy | Same | 116 | 65 | ||
| Improving | 307 | 150 | 0.59 (0.43-0.80) | <.001 | |
| Progressive | 90 | 50 | 1.05 (0.72-1.52) | .8 | |
| HMAs | Same | 86 | 44 | ||
| Improving | 168 | 101 | 1.08 (0.76-1.55) | .7 | |
| Progressive | 59 | 41 | 2.12 (1.38-3.25) | <.001 | |
| Other | Same | 42 | 60 | ||
| Improving | 95 | 37 | 0.94 (0.58-1.52) | .8 | |
| Progressive | 53 | 24 | 1.82 (1.07-3.07) | .03 | |
| Untreated | Same | 165 | 75 | ||
| Improving | 67 | 37 | 1.02 (0.69-1.52) | .9 | |
| Progressive | 179 | 77 | 0.99 (0.72-1.37) | >.99 | |
| Adjustment factors | |||||
| IPSS-R score at diagnosis | Very low | 78 | 29 | ||
| Low | 309 | 143 | 1.32 (0.88-1.98) | .17 | |
| Intermediate | 453 | 226 | 1.75 (1.16-2.63) | .007 | |
| High | 373 | 215 | 2.46 (1.61-3.75) | <.001 | |
| Very high | 214 | 148 | 3.73 (2.39-5.82) | <.001 | |
| Interval from diagnosis to HCT | 1427 | 761 | 1.03 (0.99-1.08) | .1 | |
| Age at HCT (dec) | 1427 | 761 | 1.07 (1-1.16) | .06 | |
| Conditioning | Standard | 482 | 239 | ||
| Reduced | 945 | 522 | 1.11 (0.94-1.31) | .2 | |
| Donor | Related | 515 | 260 | ||
| Unrelated | 912 | 501 | 1.13 (0.97-1.31) | .12 |
| Risk factor . | Group . | N . | D . | HR (95% CI) . | P . |
|---|---|---|---|---|---|
| Pretreatment × IPSS-R score change | |||||
| Chemotherapy | Same | 116 | 65 | ||
| Improving | 307 | 150 | 0.59 (0.43-0.80) | <.001 | |
| Progressive | 90 | 50 | 1.05 (0.72-1.52) | .8 | |
| HMAs | Same | 86 | 44 | ||
| Improving | 168 | 101 | 1.08 (0.76-1.55) | .7 | |
| Progressive | 59 | 41 | 2.12 (1.38-3.25) | <.001 | |
| Other | Same | 42 | 60 | ||
| Improving | 95 | 37 | 0.94 (0.58-1.52) | .8 | |
| Progressive | 53 | 24 | 1.82 (1.07-3.07) | .03 | |
| Untreated | Same | 165 | 75 | ||
| Improving | 67 | 37 | 1.02 (0.69-1.52) | .9 | |
| Progressive | 179 | 77 | 0.99 (0.72-1.37) | >.99 | |
| Adjustment factors | |||||
| IPSS-R score at diagnosis | Very low | 78 | 29 | ||
| Low | 309 | 143 | 1.32 (0.88-1.98) | .17 | |
| Intermediate | 453 | 226 | 1.75 (1.16-2.63) | .007 | |
| High | 373 | 215 | 2.46 (1.61-3.75) | <.001 | |
| Very high | 214 | 148 | 3.73 (2.39-5.82) | <.001 | |
| Interval from diagnosis to HCT | 1427 | 761 | 1.03 (0.99-1.08) | .1 | |
| Age at HCT (dec) | 1427 | 761 | 1.07 (1-1.16) | .06 | |
| Conditioning | Standard | 482 | 239 | ||
| Reduced | 945 | 522 | 1.11 (0.94-1.31) | .2 | |
| Donor | Related | 515 | 260 | ||
| Unrelated | 912 | 501 | 1.13 (0.97-1.31) | .12 |
Multivariable Cox proportional hazards models for PFS, with interactions between pretreatment and change in IPSS-R score. The total number of patients in each group and the number of events are reported in the N and D columns, respectively. The interval from diagnosis to HCT is in years, and age at HCT is in decades. Effect estimates are given with 95% CIs. Corresponding P values are calculated using the Wald test. All interaction effects between pretreatment and IPSS-R score change include both corresponding main effects.
dec, decades.